Pathobiology of Respiratory Syncytial Virus (RSV)
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (29 February 2020) | Viewed by 24757
Special Issue Editors
Interests: RNA viruses; respiratory viruses; epithelial cells; siRNA; CRISPR-Cas; host genes; innate immunity; adaptive immunity; anti-viral immunity
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Respiratory Syncytial Virus (RSV), a member of the Paramyxoviridae family, is the leading cause of lower respiratory tract illness in infants and also affects the elderly and the immune-compromised. RSV apically infects ciliated respiratory epithelial cells often leading to bronchiolitis, characterized by mucus in the airways, sloughed epithelial cell debris, and abundant neutrophils. Airway mucus contributes to pulmonary obstruction, but the mechanisms of RSV-induced mucus expression remain unclear. Though mice are semi-permissive for RSV replication, they have been the model of choice because they nonetheless contribute to a better mechanistic understanding of the immune response to RSV. Immune and disease correlates are under investigation in animal models and humans as there is currently no approved RSV vaccine, and therapeutics are limited. This Special Issue on “Pathobiology of Respiratory Syncytial Virus (RSV)” will cover all aspects of RSV pathogenesis, RSV immunity, RSV modulation of host responses, and RSV vaccines and antivirals.
Prof. Dr. Ralph A. Tripp
Prof. Dr. Paul Mcnamara
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- respiratory syncytial virus
- lung disease
- airways
- bronchiolitis
- vaccine
- therapeutics
- innate immune response
- adaptive immune response
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.